Asthma spacers, also known as asthma spacing chambers or volumatic devices, are used as an accessory device with pressurized metered dose inhalers (pMDIs) for administering asthma medications. Asthma spacers provide a means of delivering medications directly to the lungs by helping to coordinate activation of the pMDI with inhalation. They reduce the need for complex inhaler techniques and allow more medication to reach the lungs. Commonly used asthma spacers are single-use disposable spacers and reusable spacers.

The Global Asthma Spacers Market is estimated to be valued at US$ 2.15 Bn in 2024 and is expected to exhibit a CAGR of 19% over the forecast period from 2024 to 2030.

Key Takeaways

Key players operating in the Asthma Spacers Market are Merck KGaA, Thermo Fisher Scientific, Origene Technologies, Inc., New England Biolabs, GenScript, GeneCopoeia, Inc., Cellecta, Inc., Agilent Technologies, Inc., PerkinElmer, Inc. (Horizon Discovery Ltd.), and Danaher Corporation (Integrated DNA Technologies), among others. The rising incidence and prevalence of asthma across the world has significantly boosted the demand for asthma spacers. According to WHO, around 235 million people suffer from asthma globally. Furthermore, increasing awareness regarding proper medication management of asthma and favorable reimbursement policies for medicines have also propelled the use of asthma spacers.

The growing demand for asthma spacers in emerging economies is expected to drive the global asthma spacers market growth during the forecast period. Factors such as large population base suffering from asthma, rising healthcare expenditure, increasing awareness about disease management, and expansion of healthcare infrastructure in developing countries are expected to support market growth. Furthermore, several market players are focusing on expanding their operations in high potential emerging markets of Asia Pacific, Latin America, and Middle East & Africa, which will fuel the asthma spacers market revenue in the coming years.

The global asthma spacers market Size has witnessed consolidation with key market players focused on enhancing their global footprint. Mergers and acquisitions along with collaborations with regional market players have helped them establish global presence. For instance, in 2021, Thermo Fisher Scientific acquired PeproTech for approximately $1.85 billion to strengthen its position in the research market with capabilities in proteins and cell culture. Furthermore, companies are investing in advanced spacer device technologies and new product launches to garner greater market share globally. For instance, Propeller Health launched its SensorFlow digital inhaler that integrates sensor technology with asthma spacers to track medication use and improve adherence.

Market drivers

The growing prevalence of asthma worldwide owing to rising environmental pollution levels and changes in lifestyle factors is a key driver propelling the asthma spacers market growth. Asthma is one of the most common chronic diseases among children. As per WHO, an estimated 262 million people suffer from asthma globally. Additionally, growing awareness regarding proper medication management of asthma, especially among children, has also increased the adoption of asthma spacers when using pMDIs. This is expected to have a positive impact on the overall market revenue during the forecast period.

The current geopolitical situations are impacting the growth of the Asthma Spacers market. The rising tensions between various countries is resulting in reduced global collaboration and trade. This is hampering the movement of raw materials and medical devices across borders. The spacer devices market is dependent on imports and exports to serve patients globally. Any disruption in trade due to political instability negatively affects the timely availability of asthma spacers in different markets.

Furthermore, the ongoing conflicts and wars in some regions is leading to increased healthcare expenditure and focus being directed towards treating conflict injuries. This is diverting resources away from non-communicable diseases management like asthma. The political and economic instability in many developing nations is also reducing the priority and funding given to chronic disease management. This poses challenges for the uptake of asthma spacers in such low and middle income countries.

To ensure continued growth, companies operating in this market need to focus on developing local manufacturing and supply chain capabilities. Establishing production facilities within geographical regions will make the supply chain more self-reliant and resilient to geopolitical risks. Partnerships with local distributors and healthcare providers also help in addressing political barriers and serving customer needs even during times of global tensions. Adopting flexible pricing models tailored for different markets will further aid in improving access to asthma treatment devices.

Europe accounts for the largest share of the global Asthma Spacers market in terms of value. This is attributed to the growing asthma patient pool, rising environmental pollution levels, favorable reimbursement policies, and increasing adoption of inhaled therapy across the region. However, the Asia Pacific region is projected to witness the fastest growth during the forecast period due to the improving healthcare infrastructure, rising awareness about respiratory diseases, and expansion efforts by leading market players in developing countries.

North America currently captures a significant market value share and is anticipated to maintain its position as a prominent regional market. This is credited to the high diagnosis and treatment rates for asthma, robust research activities, and advanced healthcare systems in the US and Canada. Meanwhile, Latin America and Middle East & Africa offer lucrative prospects for asthma spacers manufacturers given the rising incidence of allergies and chronic respiratory conditions in these underserved regions.

Get more insights on: